|
Subgroup analyses
|
N (%)
|
T2DM with DPN*
|
T2DM without DPN
|
SMD (95% CI)
|
Heterogeneity
|
|---|
|
Mean + SD
|
Mean + SD
|
P-value**
|
I-squared
|
|---|
|
Ethnicity
|
Asia
|
26
|
134.64 + 18.81
|
132.26 + 16.55
|
−2.38 (−3.81 - -0.95)
|
<0.001
|
85.70
|
|
Europe
|
2
|
150.27 + 11.45
|
144.66 + 9.85
|
−5.61 (−12.66–1.45)
|
0.03
|
78.38
|
|
America
|
1
|
146.00 + 23.00
|
142.00 + 22.00
|
−4.00 (−8.35–0.35)
|
NA
|
NA
|
|
Study type
|
Case control
|
6
|
134.52 + 18.59
|
133.58 + 17.99
|
−0.94 (− 5.49–3.61)
|
<0.001
|
91.33
|
|
Cohort
|
2
|
148.07 + 21.20
|
145.00 + 20.10
|
−3.07 (−6.25–0.11)
|
0.54
|
0.00
|
|
Cross-sectional
|
21
|
135.57 + 18.67
|
132.51 + 16.43
|
−3.06 (− 4.55 - -1.57)
|
<0.001
|
83.99
|
|
Total (Random Effect Model)
|
29 (100)
|
141.08 + 19.10
|
138.45 + 18.50
|
−2.63 (− 4.00 - -1.27)
|
<0.001
|
84.88
|
- *The negative combined effect suggests that the LDL mean was higher in the non- type 2 diabetic peripheral neuropathy comparable group i.e. diabetes whereas the positive value would suggest greater LDL mean values in the type 2 diabetic peripheral neuropathy group
- **P-values is calculated LDL mean between the T2DM with and without DPN
- All LDL is reported in mmol/L
- Abbreviations: N, number; T2DM, type-2 diabetes mellitus; DPN, diabetic peripheral neuropathy; SMD, standardized mean difference; Cl: Confidence interval
